Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Von Eschenbach Defends FDA Action On Plan B During Confirmation Hearing

This article was originally published in The Pink Sheet Daily

Executive Summary

Acting commissioner defers when asked if he would accept a recess appointment to the FDA commissioner post, which would expire with the end of the next congressional season.

You may also be interested in...



Von Eschenbach Nomination Scheduled For Senate HELP Committee Vote

Senate Democrats are reviewing the nominee’s answers to their questions from an Aug. 1 hearing.

Von Eschenbach Nomination Scheduled For Senate HELP Committee Vote

Senate Democrats are reviewing the nominee’s answers to their questions from an Aug. 1 hearing.

Bush Nominates Acting NCI Chief For The Job

President George W. Bush announced Aug. 16 that he will nominate acting National Cancer Institute Director John Niederhuber to succeed Andrew von Eschenbach, who left the position to head up FDA

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064643

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel